The Press Centre provides you with access to downloadable resources on relating to the ICMA and key current clinical trials, including:
PROTECTION®
PROTECTION® Backgrounder
PROTECTION® Backgrounder concise versionPritor®/Kinzal®
Pritor®/Kinzal® Product InformationDisease
Disease BackgrounderTelmisartan
Telmisartan BackgrounderONTARGET®
ONTARGET® Backgrounder
ONTARGET® Study DesignPress releases
ACC Press release - 2008-0133 - English
ACC Press release - 2008-0133 - German
Presentations ACC Press Roundtable Presentations
ACC Press Roundtable Abstracts
Oct 25, 08: Review of ONTARGET® Trial Results: Pritor®/Kinzal® - The Angiotensin II Bloc
Jun 18, 08: Adalat® GITS and Pritor®/Kinzal® offer benefits for blood pressure control and cardiovascular protection
Apr 18, 08: New antihypertensive PritorPlus® 80/25 and Kinzalkomb® 80/25 approved by EU commission - English
Apr 18, 08: New antihypertensive PritorPlus® 80/25 and Kinzalkomb® 80/25 approved by EU commission - German
Mar 31, 08: Pritor®/Kinzal® as protective as current gold standard - English
Mar 31, 08: Pritor®/Kinzal® as protective as current gold standard - German
Sep 22, 07: Pritor®/Kinzal® offers more protection for CV patients
Oct, 06: Effective 24-hr blood pressure lowering and end-organ protection
Jan, 06: Bayer HealthCare purchases Pritor business from GlaxoSmithKline
